Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis
This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
S Reis, MI Metzendorf, R Kuehn… - Cochrane Database …, 2023 - cochranelibrary.com
Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
H Tian, C Yang, T Song, K Zhou, L Wen… - Reviews in Medical …, 2023 - Wiley Online Library
Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …
Safety and efficacy of outpatient treatments for COVID-19: real-life data from a regionwide cohort of high-risk patients in Tuscany, Italy (the FEDERATE cohort)
T Manciulli, M Spinicci, B Rossetti, RM Antonello… - Viruses, 2023 - mdpi.com
Early COVID-19 treatments can prevent progression to severe disease. However, real-life
data are still limited, and studies are warranted to monitor the efficacy and tolerability of …
data are still limited, and studies are warranted to monitor the efficacy and tolerability of …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
Real-world effectiveness of nirmatrelvir/ritonavir on coronavirus disease 2019–associated hospitalization prevention: a population-based cohort study in the province …
JL Kaboré, B Laffont, M Diop, MR Tardif… - Clinical Infectious …, 2023 - academic.oup.com
Background Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death
before Omicron, but updated real-world evidence studies are needed. This study aimed to …
before Omicron, but updated real-world evidence studies are needed. This study aimed to …
[HTML][HTML] Estimated impact of oral nirmatrelvir; ritonavir on reductions in hospitalizations and associated costs within high-risk COVID-19 patients in the US
R Sandin, C Harrison, F Draica, TL Wiemken, C Ma… - 2022 - europepmc.org
Background: SARS-CoV-2 (COVID-19) virus is estimated to cost the United States (US)
economy trillions of dollars over the next decade. Mass immunization has played a major …
economy trillions of dollars over the next decade. Mass immunization has played a major …